QuantuMDx - Changing healthcare, Globally

QuantuMDx Group Logo
Q-POC™
Tackling humanitarian
health priorities
Malaria, TB & HIV diagnosis and drug resistance status for a few dollars
Q-POC™
The Handheld Laboratory
15 minute disease diagnosis at the
touch of a button
Q-POC™
Personalising Medicine
Right first time prescribing for your patients
Q-POC™
Digitizing Biology
Translating DNA the code of life into binary code
Q-POC™
One Device,
Endless Possibilities
Flexibility to extract and analyse DNA from most sample types
Our Commercial testing laboratory
One Device, Endless Possibilities™
Q-POC™: The Handheld Laboratory

Q-POC™: The Handheld Laboratory.
QuantuMDx is The Future. Our handheld laboratory will deliver complex diagnostics in minutes for a few dollars in any setting across the globe.

QuantuMDx is The Future

Our handheld laboratory will deliver complex diagnostics in
minutes for a few dollars in any setting across the globe.

 

Making disease eradication a reality

Q-POC™ our handheld laboratory, will provide health workers with the definitive tool
to diagnose, manage, monitor and track emerging infections and drug resistance.

 

  • Results in 10-15 minutes
  • Disease diagnosis & drug resistance testing
  • Directs right first time prescribing
  • Handheld, user friendly, low cost
  • Single button operation
  • Mobile data connection

Our Devices

CEO Elaine Warburton OBE attended BIO CEO & Investor Conference as part of a UKTI Market Visit

Mayor of London Boris Johnson was one of many attendees excited about the Q-POC device.

CSO Jonathan O’Halloran chaired the Point of Care Diagnostics Symposia at Molecular Medicine Tricon in San Francisco...

and was back in the UK for a half marathon the following day!

Business Development Executive Maggie Love is looking forward to the Africa Healthcare Summit

including meetings with Ministries of Health.

CEO Elaine Warburton will speak at the Royal Society of Medicine’s Recent Developments in Digital Health

this week, giving attendees a glimpse of the future of diagnostics.

QuantuMDx invited to Wellcome Trust’s Review of Antimicrobial Resistance

Jonathan O’Halloran has been invited to sit on a diagnostics panel at the Wellcome Trust’s first event of the Review of Antimicrobial Resistance, an event tackling a crisis for the health and wealth of nations.
Read more >

QuantuMDx attending JP Morgan Healthcare Conference in San Francisco

If you would like to meet, please email Maggie Love - info@quantumdx.com

QuantuMDx attending Arab Health in Dubai

If you would like to meet, please email Maggie Love - info@quantumdx.com

Double honours as CSO named ‘Pioneer’ and CEO one of ‘50 Movers & Shakers in BioBusiness 2014’

CEO Elaine Warburton was named a BioBusiness Mover & Shaker by BioBeat in a report on women challenging the status quo in Britain, while CSO Jonathan O’Halloran was titled ‘Pioneer’ by Connected World for his Internet of Life vision.
Read more >

QuantuMDx exhibiting at MEDICA 2014

The company will be exhibiting, with a stand at E22 in Hall 1, and non-working demo Q-POC devices on hand. On Thursday at 4pm a stand party will be held sharing “A Taste of North East England”, with Newcastle Brown Ale and Durham Gin available.
Read more >

FIND and QuantuMDx partnering to developing breakthrough technology for tuberculosis detection and drug resistance determination

FIND, a Geneva-based non-profit organization and QuantuMDx Group, a British medical device developer are joining forces in developing a paradigm changing solution for the combined detection of and drug susceptibility determination for the causative agent for tuberculosis. Based on the molecular detection of an extensive set of genetic markers by the simple handheld Q-POC™ device developed by QuantuMDx, the time for full antimycobacterial resistance profiling will be reduced from weeklong to less than half an hour.
Read more >

QuantuMDx announce prototype handheld lab for 15 minute DNA-based diagnosis

At the TEDMED 2014 conference, medical device developers QuantuMDx Group announced the successful production of their first fully-integrated sample-to-result working prototype of Q-POC™, a handheld lab that delivers your DNA-based medical diagnosis in minutes. The Group believes the future of disease management and drug resistance monitoring is networked geo-stamped data, a functionality provided by the handheld Q-POC™ device. Rapid and low cost testing will enable continuous monitoring of disease and antimicrobial resistance throughout populations, as well as surveillance for emerging novel pathogen threats such as Ebola.
Read more >

 
QuantuMDx DevicesQuantuMDx investment opportunitiesQuantuMDx MissionQuanutMDx bio technololgyQuantuMDx developing new assays